Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)Alberto Bresciani, Larry C. Park, Antonino Missineo et al.|Archives of Biochemistry and Biophysics|2017Cited by 45
Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular DiseasesSergio Mallart, Stéphane Illiano, Raffaele Ingenito et al.|Journal of Medicinal Chemistry|2021Cited by 29
Salivary metabolomics in oral cancer: A systematic reviewRita Antonelli, Marco Meleti, Giacomo Setti et al.|Oral Oncology Reports|2024Cited by 10
A21 Development of an Nrf2-KEAP1 protein-protein disruptor for proof of conceptAlberto Bresciani, Larry Park, Mauro Cerretani et al.|Journal of Neurology Neurosurgery & Psychiatry|2016Cited by 2